New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
08:14 EDTAZN, CGIXCancer Genetics announces partnership with AstraZeneca
Cancer Genetics (CGIX) has been selected by AstraZeneca CAMCAR, a division of AstraZeneca (AZN), serving Central American and Caribbean countries, to provide biomarker-based diagnostic testing for cancer. Under the terms of the agreement, CGI will perform complex testing for diagnosis and prognosis of cancer patients in Central America and the Caribbean. CGI will work in close conjunction with AZ-CAMCAR on exploring expansion opportunities into additional geographic territories, further oncology categories, and into select oncology trials. The relationship is expected to concentrate on multiple cancer categories, with lung cancer being an initial area of focus.
News For CGIX;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 17, 2015
06:50 EDTAZNAstra reports median progression free survival of 13.5 months in AURA study
Subscribe for More Information
April 16, 2015
09:18 EDTCGIXOn The Fly: Pre-market Movers
Subscribe for More Information
09:12 EDTAZNAstraZeneca granted orphan status for melanoma treatment
Subscribe for More Information
08:04 EDTCGIXCancer Genetics receives NY State licensure for FHACT cervical cancer test
Subscribe for More Information
07:58 EDTAZNAstraZeneca's MedImmune, Immunocore announce new collaboration agreement
Subscribe for More Information
April 15, 2015
11:50 EDTAZNAstraZeneca initiated with a Buy at Societe Generale
07:41 EDTAZNEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
12:06 EDTAZNFDA panel accepts Onglyza's safety profile in 13-1 vote
Subscribe for More Information
07:15 EDTAZNFDA Endocrinologic & Metabolic Drugs Advisory Committee holds a meeting
Subscribe for More Information
April 13, 2015
08:58 EDTAZNMerck may have positive read through from briefing docs, says SunTrust
Subscribe for More Information
08:54 EDTAZNAstraZeneca has negative read through from briefing docs, says SunTrust
Subscribe for More Information
April 10, 2015
10:36 EDTAZNAstraZeneca trades lower, levels to watch
Shares are down less than 1% to $69.54 at time of writing. At that price the stock is just above the 50-day moving average at $69.12. Since May of last year, price has oscillated around the 50-day, with the average acting as the approximate center line. Support below the 50-day is at $68.24.
09:25 EDTAZNFDA staff say analysis suggests Onglyza may increase risk of death
Subscribe for More Information
April 9, 2015
10:00 EDTCGIXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Adobe (ADBE) initiated with an Overweight at Stephens... Aimco (AIV) initiated with a Neutral at Janney Capital... Akamai (AKAM) initiated with a Hold at Deutsche Bank... Anadarko (APC) initiated with an Outperform at BMO Capital... Apache (APA) initiated with a Market Perform at BMO Capital... Arista Networks (ANET) initiated with a Neutral at Wedbush... AvalonBay (AVB) initiated with a Neutral at Janney Capital... BioScrip (BIOS) initiated with a Buy at Craig-Hallum... Brinker (EAT) initiated with a Buy at Longbow... Broadcom (BRCM) initiated with a Buy at Ladenburg... Camden Property (CPT) initiated with a Neutral at Janney Capital... Canadian National (CNI) initiated with an Overweight at Atlantic Equities... Canadian Pacific (CP) initiated with an Overweight at Atlantic Equities... Cancer Genetics (CGIX) initiated with a Buy at Janney Capital... Denny's (DENN) initiated with a Buy at Longbow... Equity Residential (EQR) initiated with a Neutral at Janney Capital... Essex Property Trust (ESS) initiated with a Neutral at Janney Capital... Fifth Third (FITB) initiated with a Buy at Evercore ISI... Garrison Capital (GARS) initiated with a Buy at Maxim... GrubHub (GRUB) initiated with a Hold at Wunderlich... Hess Corp. (HES) initiated with a Market Perform at BMO Capital... Home Properties (HME) initiated with a Buy at Janney Capital... Huntington Bancshares (HBAN) initiated with a Buy at Evercore ISI... Intersect ENT (XENT) initiated with a Buy at CRT Capital... Jack in the Box (JACK) initiated with a Neutral at Longbow... KeyCorp (KEY) initiated with a Hold at Evercore ISI... LogMeln (LOGM) initiated with a Neutral at JPMorgan... Marathon Oil (MRO) initiated with a Market Perform at BMO Capital... Marvell (MRVL) initiated with an Outperform at Cowen... Masonite (DOOR) initiated with an Outperform at Macquarie... Mid-America Apartment (MAA) initiated with a Buy at Janney Capital... Natures Sunshine Products (NATR) initiated with an In-Line at Imperial Capital... Nielsen (NLSN) initiated with an Outperform at Telsey Advisory... Plug Power (PLUG) initiated with an Equal Weight at Morgan Stanley... Post Properties (PPS) initiated with a Neutral at Janney Capital... QTS Realty Trust (QTS) initiated with a Buy at Evercore ISI... Rentrak (RENT) initiated with an Outperform at Telsey Advisory... RiceBran (RIBT) initiated with a Buy at Maxim... StarTek (SRT) initiated with a Buy at Lake Street... Tribune Media (TRCO) initiated with an Outperform at Wells Fargo... TrueCar (TRUE) initiated with a Hold at Wunderlich... UDR, Inc. (UDR) initiated with a Neutral at Janney Capital... comScore (SCOR) initiated with a Market Perform at Telsey Advisory.
09:25 EDTAZNPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
06:56 EDTCGIXCancer Genetics initiated with a Buy at Janney Capital
Subscribe for More Information
April 8, 2015
06:06 EDTAZNInovio selected by DARPA to lead $45M Ebola prevention program
Subscribe for More Information
April 7, 2015
16:12 EDTAZNRegulus up 5% after RG-125 selected as clinical candidate by AstraZeneca
Subscribe for More Information
16:12 EDTAZNRegulus RG-125 selected as clinical candidate by AstraZeneca
Regulus Therapeutics (RGLS) announced the selection of RG-12, a GalNAc-conjugated anti-miR targeting microRNA-103/107, or miR-103/107, for the treatment of Non Alcoholic Steatohepatitis, or NASH, in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca (AZN) under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics. RG-125 is the first compound from the alliance to be selected for clinical development by AstraZeneca. In connection with the candidate selection, AstraZeneca will pay Regulus $2.5M and will assume development of the program following acceptance of an Investigational New Drug application. In the near term, Regulus and AstraZeneca plan to submit key preclinical data on the RG-125 program to be presented at a scientific meeting later this year and expect to initiate a Phase I study of RG-125 in humans by the end of 2015.
07:14 EDTAZNEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use